MASITINIB IN THE TREATMENT CANINE GRADE 2/3 MAST CELL TUMORS THAT ONLY EXPRESS WT C-KIT

摘要

Masitinib is a tyrosine kinase inhibitor targeting c-Kit, the growth factor receptor of mast cells. Masitinib inhibits both constitutively active mutated forms of c-Kit (found in 25% of mast cell tumors, MCTs) and wild type (WT) c-Kit.Methods: The efficacy of masitinib in MCTs was tested in a multicenter, randomized, placebo-controlled, double-blind study. Two-hundred-and-two dogs with recurrent or non-resectable grade 2/3 MCTs, including 139 dogs with WT c-Kit tumors, received eithermasitinib (12.5 mg/kg/day) or placebo. Endpoints were tumor response/progression (WHO criteria) and survival.